drugset / Trial / NCT00460031
Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as ketoconazole, may stop the adrenal glands from making androgens. Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. Giving ketoconazole and hydrocortisone together with lenalidomide may be an effective treatment for prostate cancer. PURPOSE: This phase II trial is studying how well giving ketoconazole and hydrocortisone together with lenalidomide works in treating patients with prostate cancer that did not respond to hormone therapy.
Timeline
- Start
- 2006-09-01
- Primary completion
- 2010-08-31
- Completion
- 2010-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketoconazole | Small molecule | 400 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | 10 mg | Oral |
| Background | Hydrocortisone | Other / unclassified | 20 mg | Oral |